go for the jugular

$ELV and $HCA highlighting why $TOI is likely one of the best positioned companies in healthcare. The highlight of $ELV quarter was Carelon, which is analogous to $TOI valuable dispensary business, and they also called out oncology as a notable growth area. Meanwhile, their still uncontained cost trend means more reliance on low cost partners like $TOI (ELV is their largest customer) Meanwhile, $HCA commentary highlights risks for exchange-exposed players like $EVH, which still carry a premium valuation to $TOI even though $TOI is insulated from exchange headwinds.

$TOI might be the most under-the-radar turnaround under $10 right now. The Oncology Institute. A value-based cancer care company. The stock is up 121% in the past year — and almost nobody on FinTwit is talking about it. Last quarter it grew revenue 41% and narrowed its loss by 87%. Analysts just raised the target to $7.75. It trades around $5.25. Here's the full DD. 🧵👇

Folks (guys and gals), don't be psyopped by this article. You don't have unlimited time. You need to be moving. Don't put off life. Don't look at Anne Hathaway getting pregnant at 43 and think "Oh, ok I'll be fine." It's a psyop. You'll have massive regret if you squander your youth with hedonism and selfish BS and then try to scramble to have a real life later. Don't be deceived by lies.

@Carflos223Matos @chat_SBC @taobanker I’m in the Nov 2026 200 calls ser Time to torque it

@chat_SBC You long now @chat_SBC ? @taobanker what we think

$ORCL down 50% with codex ramping + 5.6 benchmarks. not that long ago bulls were calling for $300 and still can get there in 2 years. R/R pretty nuts right now

Never forget that you are the main data center. Drink water, and consume as much literature as possible.

terrible time to have a history degree & pattern recognition skills

@unciacapital cc @rev_cap who will disagree with me massively

the market more afraid of growth downside than growth upside imo. that's natural with equities at all time highs and the drivers of the econ being so correlated (AI capex, wealth effect). i would be very surprised if marginal hawkishness gets you higher rates across the curve. forward indications of inflation have plummeted. a fed that wants to destroy demand to fight various supply side inflationary impulses is just going to massively flatten the curve. to your point, once the 30yr comes down to 4.75 or so and 5s30s comes <50bps, the fed will get the memo and back off. equities will probably suffer in the meantime.

Starting w/ the 3 month yield, the entire U.S. yield curve is ABOVE the upper end of the Fed Funds target rate (3.75%). Usually the yield curve gets it right and the Fed follows. Basically, yield curve is saying hike incoming (timing uncertain); would also explain why gold $GLD has been weak. CPI & PPI this week will be interesting. I am biased to think rates go higher this year.

$TOI · $6.21 The Oncology Institute, Inc.: Overweight Executive Summary: TOI presents a compelling but high-risk opportunity: 41.22% YoY revenue growth (per Fundamentals Overview) with sequential acceleration to $147.4M in Q1 2026, losses narrowing 85% from -$16.5M to -$2.5M across three quarters (per Income Statement), and a transformative July 7 OrbiMed refinancing replacing $86M Deerfield convertible debt with a $75M term loan maturing 2031 (per News Articles). However, the Altman Z-Score of 0.65, negative equity of -$16.3M, Debt/Assets at 0.98x, and negative FCF in 4 of 5 quarters (per Fundamentals Overview and Cash Flow Statement) signal deep balance sheet distress. The stock has rallied 72% to $5.89 (per Price Data) and is overbought. Strategy: accumulate gradually on pullbacks to $5.00-$5.30, limit position to 1.5-2.0% of portfolio, set stop at $4.45. Target $8.00 over 6-12 months. Key catalyst: Q2 2026 earnings to confirm post-refinancing balance sheet improvement and operating cash flow trajectory. Price Target: $8.0 Time Horizon: 6-12 months Tradelyzer© uses the latest SEC data All data sourced from paid APIs NFA DYOR. Edutainment only #Investing #TradingSignals #Stocks

Stoic Capital was early to $TOI in 2025 - great blog, highly recommend. Link in bio below

long $RBSTF

Jorey is just going to buy the entire company at this pace. Very long $TOI

$TOI now up +100% from the lows, and still looks cheap.

do or die level for $ORCL chillin at the 52 week low

bitcoin is made of long term holders metrics at an all-time high: - supply last active ≥ 10 years (17.7%) - long-term-holder supply (16.75M) - long-term-holder realized cap ($836.4B) - long-term-holder realized price ($50k)

Joel Greenblatt from The Little Book That Beats The Market: you must do it yourself.

Conviction is when you are frustrated that a stock is not down more.

How life starts to feel when you stop taking work so seriously

$TOI mention on biz TV where host has 1M+ followers certainly puts the stock in the “mainstream”. To mark the occasion, a longer thread about the phases of investing in a successful small cap. Being aware of these phases can provide insight on trading dynamics in small cap… Technical analysis on small caps rarely works. Technicals presume informed market participants are driving prices. The reality in small caps is that those doing technical analysis usually don’t know what they are doing, and gap risk can change your chart quickly. But it is a truism that stock prices are determined by supply and demand of holders for a stock at a given price. Each small cap phase has different supply and demand of holders, determined by fundamental and technical constraints. Fundamental constraints are things like research capacity and other resources to develop conviction. Technical constraints are things like volatility tolerance and liquidity parameters. Phase 1 for a small cap is the discovery phase. The stock is under-followed, and so liquidity is low and volatility is high. This is the domain of certain individual investors and small funds. They are often breaking new ground with research and able to tolerate a liquidity / volatility profile that does not obviously justify the investment of research resources, perhaps because the position is a “starter” that they expect to follow for a long time or they have greater freedom with their own capital than is the case with other peoples’ money. Phase 2 is the amplification phase. The stock gets picked up by retail day traders and their social media heroes. Even as the fundamental thesis is discussed more broadly, fundamental conviction amongst this new group of investors is low because of research capacity constraints (people capable of maintaining 20-30 “high conviction” ideas are rare, and your favorite finance blogger probably isn’t one of them). This means more volatility as “price action” figures prominently in buyers’ and sellers’ reaction functions, but generally leads to more liquidity as shares change hands more frequently. Phase 3 is the consolidation phase. This usually occurs as a reaction to a real or perceived short-term disappointment. Larger individual investors and institutions with a longer time horizon or more deeply researched view, often those present from Phase I, accumulate shares using higher liquidity provided by those exiting based price or focus on short-term events. Shares consolidate into fewer hands, liquidity declines and usually volatility does too once the transition of holders is complete. Phase 4 is the validation phase. Company execution validates a thesis that attracts the attention of more, and larger, fundamental investors that are willing to take a risk by betting on that execution trend continuing. At the same time, a rising share price often brings about selling from long-time holders who need liquidity, especially legacy private equity backers. New buyers and sellers bring about improving liquidity. Volatility picks back up as well, generally as the market grapples with pricing remaining idiosyncratic risks (often related to determining a sustainable capital structure or long-term unit economics). Phase 5 is the mainstream phase. Those remaining idiosyncratic risks get resolved or become better understood, making the stock “ownable” for mainstream institutions. Liquidity improves even more as new market participants enter the fray, and volatility declines with more informed market participants transacting in the stock. This certainly does not mean there is no longer attractive upside in the stock, it just means less squirrelly small cap trading. Indeed, this is often the beginning of multiple expansion as the “risk premium” associated with squirrelly trading are priced out. Anyone following TOI over the last 18 months will recognize each of these phases, and hopefully this framework sheds some light on other situations and opportunities

On this day 9 years ago, history was made.